Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Integris Medtech IPO
Price Band
₹
Issue Size
—
Lot Size
—
Min Investment
—
GMP
—
Issue Price
—
Integris Medtech IPO AI Summary
- Integris Medtech IPO is upcoming on BSE, NSE in the Medical Equipment & Supplies sector.
- Subscription window: 27 Nov–01 Dec 2026, listing on 04 Dec 2026.
Integris Medtech Ltd is preparing for an IPO with a focus on expanding its medical device and laboratory solutions business. Despite recent profitability improvements, potential investors should weigh the company's market position against the inherent risks of investing in IPOs.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Important Dates
Subscription Status
IPO not open yet
Opens 27 Nov 2026 · in 7 days
Integris Medtech IPO Grey Market Premium (GMP) Today
GMP not available yet
Grey Market Premium is updated daily. Check back closer to the listing date.
TopFund Score — Listing Data Indicator
GMP not yet available
Subscription not open yet
No anchor allocation for this IPO
Similar IPOs (same IPO type) averaged 17.8% listing gain
A rules-based composite of GMP, subscription demand, anchor participation and comparable-IPO history — each weighted as shown above. Not a statistically validated probability, a guarantee of listing performance, or personalized investment advice.
Limitations: weights are fixed by TopFund, not backtested against outcomes; the "Historical Similar-IPO Performance" factor needs at least 3 comparable past listings and falls back to a broader, less specific cohort when this sector/type doesn't have enough; GMP and subscription data can change daily right up to listing day, so scores shown may already be stale — check the "as of" date above.
About the Company
Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions. Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments. The company’s business is structured into two core divisions: Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions. Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand. Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors. Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America. As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.
Company Financials (₹ Cr)
As of 2025-06-30
| Period Ended | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 4,019.62 | 3,641.34 | 2,989.20 | 2,553.87 |
| Total Income | 508.93 | 1,959.58 | 1,582.26 | 1,369.66 |
| Profit After Tax | 267.57 | 70.68 | -4.88 | -40.54 |
| EBITDA | 78.73 | 309.40 | 190.45 | 168.82 |
| NET Worth | 3,889.99 | 2,752.52 | 2,681.02 | 2,629.52 |
| Reserves and Surplus | 2,299.84 | 1,150.74 | 1,135.71 | 1,073.12 |
| Total Borrowing | 793.42 | 1,729.46 | 813.10 | 556.54 |
Key Ratios
EPS
₹6.52
NAV
₹316.09
ROE
5.35%
ROCE
14.51%
RoNW
1.48%
PAT Margin
3.72%
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Laxmi Dental | 37.71 | 16.09% | 53.95 | 6.07 | 6.05 |
| Poly Medicure | 278.46 | 12.26% | 56.02 | 34.13 | 34.11 |
| Our Company This IPO | 316.09 | 1.84% | — | 5.82 | 5.73 |
Promoters
Evercure Holdings Pte.Ltd., Medicore Holdings Pte.Ltd., Gurmit Singh Chugh and Punita Sharma
Objects of the Issue
# | Issue Objects | Est Amt (₹ Cr.) 1 | Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | 509.85 2 | The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. | 93.87 3 | The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | 415.98 4 | General Corporate Purposes | | Total | 1,019.70
Pros & Cons
Strengths
- Diverse product portfolio in medical devices
- Strong international market presence
- Positive recent profit trend
Risks
- Recent negative profit figures
- Dependence on international markets
- High competition in medical equipment sector
IPO Evaluation
Generated 20 Nov 2026Revenue Trend
Total income was ₹1,369.66 Cr in the year ending 31 Mar 2023, increasing to ₹1,582.26 Cr by 31 Mar 2024. This growth continued, reaching ₹1,959.58 Cr by 31 Mar 2025, though the most recent figure of ₹508.93 Cr for the period ending 30 Jun 2025 is not directly comparable as it reflects only part of the fiscal year.
Profit Trend
Profit after tax was negative at ₹-40.54 Cr for the year ending 31 Mar 2023, improving to ₹-4.88 Cr by 31 Mar 2024. By 31 Mar 2025, profit turned positive at ₹70.68 Cr, and further increased to ₹267.57 Cr in the period ending 30 Jun 2025, though this is a 9-month figure, not a full year, so isn't directly comparable.
Valuation
The implied P/E ratio at the issue price is not calculable with the provided data.
Grey Market Premium, Explained
The grey market refers to unofficial trading of shares before they are listed on the stock exchange. Grey market premium (GMP) indicates the expected listing price compared to the issue price. A higher GMP suggests strong demand, while a lower GMP may indicate weaker interest.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk appetite and market conditions.
Who May Want to Wait
Conservative investors or those averse to market fluctuations may consider avoiding this IPO.
Listing Gains — The Risk
Listing day gains can be unpredictable. Factors influencing the stock price include market conditions, investor sentiment, and overall demand for the IPO. It's essential to consider these risks before investing.
This evaluation is generated from Integris Medtech's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
When does Integris Medtech IPO open and close?
Integris Medtech IPO opens on 27 November 2026 and closes on 01 December 2026.
When does Integris Medtech IPO list on the stock exchange?
Integris Medtech IPO is scheduled to list on 04 December 2026.
What is the TopFund Listing Data Indicator for Integris Medtech?
Integris Medtech's Listing Data Indicator score is 60/100 (Moderate signal), a weighted composite of GMP strength, subscription demand, anchor investor interest and how similar past IPOs performed on listing. It's a rules-based summary of public market data, not a statistically validated probability, a guarantee, or personalized investment advice.
What is the lot size for this IPO?
The lot size information is not available.
What is the minimum investment required?
The minimum investment details are not provided.
What is the price band for the IPO?
The price band has not been disclosed.
When does the IPO open and close?
The IPO opens on 27 Nov 2026 and closes on 01 Dec 2026.
What does GMP mean?
GMP indicates the expected premium of the stock in the grey market before listing.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
27 Nov 2026
Close
01 Dec 2026
Allotment
02 Dec 2026
Listing
04 Dec 2026
Similar IPOs in Medical Equipment & Supplies
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Integris Medtech?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.